-

02:32:40 AM

TLTFF Stock News

TLTFF - Theralase Technologies Inc.

02/02/23 7:00 AM

OTC : TLTFF

clinical trial

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the AUA Annual Meeting

Theralase® Technologies Inc. (“ Theralase® ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug

RHEA-AI

neutral

01/25/23 7:00 AM

OTC : TLTFF

clinical trial

Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium

Theralase® Technologies Inc. (“ Theralase® ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug

RHEA-AI

neutral

11/29/22 6:43 PM

OTC : TLTFF

Theralase Releases Q322 Interim Financial Statements

Theralase® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“ PDC ”) and their associated drug

RHEA-AI

neutral

09/29/22 5:00 PM

OTC : TLTFF

Theralase® Announces Warrant Extension

Theralase ® Technologies Inc. (“ Theralase ” or “ Company ”) ( TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated drug

RHEA-AI

neutral

09/22/22 5:55 PM

OTC : TLTFF

Theralase® Closes $2.5M Private Placement Equity Financing

Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated

RHEA-AI

neutral

08/29/22 7:45 PM

OTC : TLTFF

Theralase Releases Q222 Interim Financial Statements

Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“ PDC ”) and their associated drug

RHEA-AI

neutral

06/28/22 7:00 AM

OTC : TLTFF

Theralase Expands Intellectual Property Portfolio

Theralase ® Technologies Inc. (“ Theralase ® ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs ”) and their associated

RHEA-AI

positive

06/24/22 7:00 AM

OTC : TLTFF

Theralase® Research - One of the Top 10 Most Downloaded Papers

Theralase® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“ PDC ”) and their associated drug

RHEA-AI

positive

06/21/22 7:00 AM

OTC : TLTFF

clinical trial

Theralase® Phase Ib NMIBC Clinical Study Published

Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“ PDC ”) and their associated

RHEA-AI

neutral

05/30/22 5:53 PM

OTC : TLTFF

Theralase Releases Q122 Interim Financial Statements

Theralase ® Technologies Inc. (“ Theralase ” or the “ Company ”) ( TSXV: TLT) ( OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“ PDC ”) and their associated drug

RHEA-AI

neutral